We are live on ! Find out more
VCIM

Velan Capital Investment Management Portfolio holdings

AUM $160M
1-Year Est. Return 517.12%
This Fund
S&P 500
This Quarter Est. Return
-5.48%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$97.2M
AUM Growth
-$18.7M
Cap. Flow
+$16.8M
Cap. Flow %
17.25%
Top 10 Hldgs %
76.66%
Holding
55
New
10
Increased
17
Reduced
2
Closed
8

Top Buys

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$8.01M
2
SCPH
scPharmaceuticals
SCPH
+$2.99M
3
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.9M
4
VRNA
Verona Pharma
VRNA
+$2.69M
5
TELA icon
TELA Bio
TELA
+$1.84M

Top Sells

Rank Stock Value
1
PRAX icon
Praxis Precision Medicines
PRAX
+$7.18M
2
NRIX icon
Nurix Therapeutics
NRIX
+$1.84M
3
RZLT icon
Rezolute
RZLT
+$1.74M
4
KURA icon
Kura Oncology
KURA
+$1.31M
5
COLL icon
Collegium Pharmaceutical
COLL
+$822K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
51
Enanta Pharmaceuticals
ENTA
$393M
– –
-13,000
Closed -$74.8K
KYNB
52
Kyntra Bio
KYNB
$28.7M
– –
-3,200
Closed -$42.4K
KPTI icon
53
Karyopharm Therapeutics
KPTI
$46M
– –
-2,667
Closed -$27.1K
KURA icon
54
Kura Oncology
KURA
$882M
– –
-150,000
Closed -$1.31M
NRIX icon
55
Nurix Therapeutics
NRIX
$2.76B
– –
-97,889
Closed -$1.84M
1 2
3

Similar funds

BFAG
Blackston Financial Advisory Group The Villages, Florida $160M AUM 16.38% 1-Year Est. Return
SLG
Sanchez Levi Garrett $159M AUM
SMF
Sterling Manor Financial Saratoga Springs, New York $160M AUM 13.84% 1-Year Est. Return
LCA
Legend Capital Advisors New York $160M AUM
SGCM
Sanchez Gaunt Capital Management Reno, Nevada $160M AUM
RP
RIHO Partners Tucson, Arizona $159M AUM
PCC
Perry Creek Capital New York $160M AUM 3.05% 1-Year Est. Return
RCWM
Royal Capital Wealth Management Carmel, Indiana $161M AUM 18.42% 1-Year Est. Return

Velan Capital Investment Management's Q1 2025 Portfolio in Review

As of Q1 2025, Velan Capital Investment Management held 55 positions worth $97.2M, down 16% from $116M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Velan Capital Investment Management deployed $16.8M of net new capital in Q1 2025, opening 10 new positions and adding to 17 existing holdings. Its largest new stake was ACELYRIN: 3,366,945 shares worth $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Praxis Precision Medicines, an estimated $7.18M trimmed.

  • Velan Capital Investment Management's largest Q1 2025 buy was ACELYRIN: 3,366,945 shares worth $8.32M.
  • Velan Capital Investment Management added most to Zevra Therapeutics in Q1 2025, an estimated $2.9M increase.
  • Velan Capital Investment Management's biggest Q1 2025 reduction was Praxis Precision Medicines, cutting an estimated $7.18M.
  • Velan Capital Investment Management fully exited Nurix Therapeutics in Q1 2025, selling an estimated $1.84M.
  • Velan Capital Investment Management's ten largest holdings make up 77% of its $97.2M portfolio in Q1 2025.
  • Velan Capital Investment Management opened 10 new positions and closed 8 in Q1 2025.
  • Velan Capital Investment Management's portfolio value fell 16% quarter-over-quarter to $97.2M.

Based on Velan Capital Investment Management's 13F filing for Q1 2025, filed 15 May 2025.